title: Involvement of leukotriene B4 in dermatophyte-related itch in mice.
abstract: BACKGROUND
  Proteinase-activated receptor-2 (PAR2) is involved in dermatophyte-induced scratching and leukotriene B4 (LTB4) release from keratinocytes. We investigated whether PAR2-mediated LTB4 production is involved in dermatophyte-induced scratching.
  
  
  METHODS
  Dermatophyte extract was injected intradermally and scratching was observed in mice. LTB4 was determined by enzyme immunoassay.
  
  
  RESULTS
  Dermatophyte extract-induced scratching was inhibited by zileuton (5-lipoxygenase inhibitor), ONO-4057 (LTB4 antagonist), FSLLRY-NH2 (PAR2 antagonist), and anti-PAR2 antibody. Dermatophyte extract injection increased the cutaneous content of LTB4, which was inhibited by zileuton and FSLLRY-NH2.
  
  
  CONCLUSIONS
  These results suggest the involvement of LTB4 in dermatophyte-associated itch. LTB4 production might be due to PAR2 stimulation in the skin.
authors.affiliation: Department of Applied Pharmacology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Sugitani, Japan.
authors.forename: Tsugunobu
authors.initials: T
authors.lastname: Andoh
authors.affiliation: Department of Applied Pharmacology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Sugitani, Japan.
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Takayama
authors.affiliation: Department of Applied Pharmacology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Sugitani, Japan. Electronic address: kuraisiy@pha.u-toyama.ac.jp.
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Kuraishi
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D003883:Arthrodermataceae / Q000472:pathogenicity; D003881:Dermatomycoses / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D006918:Hydroxyurea / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D015603:Keratinocytes / Q000378:metabolism; D020024:Leukotriene Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D007975:Leukotriene B4 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D008297:Male; D008815:Mice, Inbred Strains; D009842:Oligopeptides / Q000008:administration & dosage / Q000627:therapeutic use; D011537:Pruritus / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism*; D044464:Receptor, PAR-2 / Q000037:antagonists & inhibitors / Q000276:immunology / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; C508716:H-Phe-Ser-Leu-Leu-Arg-Tyr-NH2; D020024:Leukotriene Antagonists; D009842:Oligopeptides; D044464:Receptor, PAR-2; D007975:Leukotriene B4; C063449:zileuton; D006918:Hydroxyurea
keywords: 5-Lipoxygenase; Dermatophyte; Itch; Leukotriene B(4); Proteinase-activated receptor 2